2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.75 USD
+0.19 (4.17%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.75 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.75 USD
+0.19 (4.17%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.75 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Zacks News
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
by Zacks Equity Research
Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.
Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates
by Zacks Equity Research
Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.
Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback
by Zacks Equity Research
Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.
2seventy bio, Inc. (TSVT) Loses -44.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal
by Zacks Equity Research
2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Senti Biosciences, Inc. (SNTI) delivered earnings and revenue surprises of 12.50% and 27.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 65.85% and 164.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 20.69% and 0.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -44.87% and 8.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More
by Zacks Equity Research
Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.
2seventy (TSVT) Down 9% on Patient Death in Leukemia Study
by Zacks Equity Research
Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.
Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use
by Zacks Equity Research
Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 9.24% and 115.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.
Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study
by Zacks Equity Research
Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.
Bristol Myers (BMY), TSVT Application for Abecma Accepted
by Zacks Equity Research
Bristol Myers (BMY) and partner TSVTs sBLA for CAR T cell therapy is accepted by the FDA for earlier lines of treatment in multiple myeloma.
bluebird (BLUE) Down on Updates on SCD Therapy, Reports Q4
by Zacks Equity Research
bluebird (BLUE) provides updates on its BLA submission for its experimental gene therapy lovo-cel and reports Q4 results. Shares are down on the same.
Harmony Biosciences Holdings, Inc. (HRMY) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.